{"id":631692,"date":"2025-03-18T13:46:21","date_gmt":"2025-03-18T17:46:21","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=631692"},"modified":"2025-10-23T16:15:31","modified_gmt":"2025-10-23T20:15:31","slug":"tirzepatide-vs-semaglutide","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/tirzepatide-vs-semaglutide\/","title":{"rendered":"Tirzepatide vs. semaglutide: Differences & similarities explained"},"content":{"rendered":"

Tirzepatide and semaglutide have exploded in popularity over the past few years, primarily due to their weight loss benefits. Tirzepatide is the active ingredient in both <\/span>Mounjaro<\/span><\/a> and <\/span>Zepbound<\/span><\/a>, while semaglutide is the active ingredient in <\/span>Ozempic<\/span><\/a>, <\/span>Wegovy<\/span><\/a>, and <\/span>Rybelsus<\/span><\/a> (an oral medicine). These medications act like natural hormones in the body, regulating appetite and reducing food noise (intrusive thoughts about food that interfere with weight loss efforts). While these drugs share some similarities, they also have some differences.\u00a0<\/span><\/p>\n

Note that while there are <\/span>compounded versions of tirzepatide and semaglutide<\/span><\/a>, these drugs are not FDA approved. This article focuses on the five FDA-approved versions of tirzepatide and semaglutide.<\/span><\/p>\n

What is tirzepatide?<\/span><\/h2>\n

Tirzepatide is the active ingredient in two medications approved by the Food and Drug Administration (FDA). <\/span>Mounjaro<\/span><\/a> is FDA approved for Type 2 diabetes but is prescribed <\/span>off-label<\/span><\/a> (for a non-FDA-approved use) for weight loss. <\/span>Zepbound<\/span><\/a> is FDA approved for weight loss and obstructive sleep apnea. These medications are given as once-weekly injections subcutaneously (under the skin). Eli Lilly manufactures both Mounjaro and Zepbound.\u00a0<\/span><\/p>\n

What is semaglutide?<\/span><\/h2>\n

Semaglutide is the active ingredient in three FDA-approved medications. <\/span>Ozempic<\/span><\/a> is used for Type 2 diabetes and cardiovascular risk reduction (lowering the risk of major adverse cardiovascular events, including cardiovascular death, heart attack, and stroke) and is commonly prescribed off-label for weight loss. <\/span>Wegovy<\/span><\/a> is FDA approved for weight loss and cardiovascular risk reduction. Ozempic and Wegovy are given as once-weekly subcutaneous injections. <\/span>Rybelsus<\/span><\/a> is a tablet that is taken by mouth once a day. It is FDA approved for Type 2 diabetes. Novo Nordisk manufactures Ozempic, Wegovy, and Rybelsus.<\/span><\/p>\n

RELATED: <\/b>How long can you take semaglutide?<\/b><\/a><\/p>\n

Tirzepatide vs. semaglutide: Key differences<\/span><\/h2>\n

Tirzepatide, which is the active ingredient in the brand-name drugs Mounjaro and Zepbound, is classified as a <\/span>glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, also known as a GIP receptor\/GLP-1 receptor agonist. Semaglutide is the active ingredient in brand-name injectable drugs Ozempic and Wegovy, as well as the brand-name oral drug Rybelsus. It is classified as a <\/span>GLP-1 receptor agonist<\/span><\/a>.\u00a0<\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Compare tirzepatide vs. semaglutide key differences<\/span><\/h3>\n<\/th>\n<\/tr>\n<\/thead>\n

<\/td>\nTirzepatide<\/b><\/td>\nSemaglutide<\/b><\/td>\n<\/tr>\n
Drug class<\/b><\/td>\nGIP\/GLP-1 agonist<\/span><\/td>\nGLP-1 agonist<\/span><\/td>\n<\/tr>\n
Brand\/generic status<\/b><\/td>\nBrand<\/span><\/td>\nBrand<\/span><\/td>\n<\/tr>\n
What is the brand name?<\/b><\/td>\n\n
    \n
  • Mounjaro<\/span><\/li>\n
  • Zepbound<\/span><\/li>\n<\/ul>\n<\/td>\n
\n
    \n
  • Ozempic<\/span><\/li>\n
  • Rybelsus<\/span><\/li>\n
  • Wegovy<\/span><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
What form(s) does the drug come in?<\/b><\/td>\nInjection<\/span><\/td>\nOzempic and Wegovy: Injection<\/span><\/p>\n

Rybelsus: Oral tablet<\/span><\/td>\n<\/tr>\n

What is the standard dosage?<\/b><\/td>\nStarting dose: 2.5 mg injected once a week. The healthcare provider will gradually increase the dose to a maximum of 15 mg injected once a week. Doses may vary based on condition, response to treatment, and side effects.\u00a0<\/span><\/td>\nStarting dose of Ozempic and Wegovy: 0.25 mg injected once a week. The healthcare provider will gradually increase the dose to a maximum of 2 mg (<\/span>Ozempic<\/span><\/a>) or 2.4 mg (<\/span>Wegovy<\/span><\/a>) injected once a week. Doses may vary based on condition, response to treatment, and side effects.<\/span><\/p>\n

Starting dose of <\/span>Rybelsus<\/span><\/a>: There are two formulations. One formulation has a starting dose of 3 mg per day, with the dose gradually increased up to a maximum of 14 mg per day. The second formulation has a starting dose of 1.5 mg per day, with the dose gradually increased up to a maximum of 9 mg per day.<\/span><\/td>\n<\/tr>\n

How long is the typical treatment?<\/b><\/td>\nLong-term\u00a0\u00a0<\/span><\/td>\nLong-term\u00a0<\/span><\/td>\n<\/tr>\n
Who typically uses the medication?<\/b><\/td>\nAdults<\/span><\/td>\nOzempic, Rybelsus: Adults<\/span><\/p>\n

Wegovy: Adults and pediatric patients 12 years and older<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Tirzepatide vs. semaglutide: Conditions treated<\/span><\/h2>\n

Tirzepatide is the active ingredient in both Mounjaro and Zepbound.<\/span><\/p>\n